<DOC>
	<DOCNO>NCT02895906</DOCNO>
	<brief_summary>This 5-week , multi-center , open-label , dose optimization trial subject age 12-17 year 22q11DS diagnosis anxiety disorder , and/or ADHD , and/or ASD . Approximately 12 subject initiate , dose optimize , maintain NFC-1 period 5 week .</brief_summary>
	<brief_title>Safety Efficacy Study NFC-1 Subjects Aged 12-17 Years With 22q11.2DS &amp; Associated Neuropsychiatric Conditions</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>DiGeorge Syndrome</mesh_term>
	<criteria>Subject diagnosis 22q11.2 deletion prior screen . Subject diagnosis anxiety disorder and/or ADHD and/or ASD base upon diagnostic evaluation perform screening , history , clinical judgement . Subject judge general good health , anxiety disorder and/or ADHD and/or ASD 22q11DS . Medical condition related 22q11DS must clinically stable post surgical correction and/or medical management . Subject clinically significant abnormality 12lead electrocardiogram ( ECG ) perform screen baseline serious arrhythmia , bradycardia , tachycardia , cardiac conduction problem , abnormality deem potential safety issue . Subject parent/legal guardian understand study procedure agree subject 's participation study indicate parental/legal guardian signature subject inform consent form subject 's signature assent form . Subject diagnosis comorbid major psychiatric disorder ( ie , aside anxiety disorder , ADHD , and/or ASD ) , include major depression , bipolar disease , schizophrenia ( psychotic disorder ) , moderate severe intellectual disability , opinion investigator may interfere conduct study evaluation . Subject IQ &lt; 65 determine Wechsler Abbreviated Scale Intelligence . Subject history illness , opinion study investigator , might confound result study pose additional risk subject his/her participation study . Subject history clinically significant endocrine , gastrointestinal , cardiovascular , hematological , hepatic , immunological , renal , respiratory , genitourinary abnormality disease currently stable clinically . Subjects history uncomplicated kidney stone may enrol study discretion investigator . Subject history stroke , chronic seizure , major neurological disorder , opinion investigator , would interfere subject 's ability participate and/or evaluate trial . Subject currently consider risk suicide ( opinion investigator ) , previously make suicide attempt , currently demonstrate active suicidal ideation . Subject take antidepressant , antipsychotic , anxiolytic , nonstimulant ADHD medication within 30 day Screening Visit . Subject take prohibited medication</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>22q11.2 DS</keyword>
</DOC>